Targeting antitumor CD4 helper T cells with universal tumor-reactive helper peptides derived from telomerase for cancer vaccine

Hum Vaccin Immunother. 2013 May;9(5):1073-7. doi: 10.4161/hv.23587. Epub 2013 Jan 28.

Abstract

Current cancer immunotherapies predominantly rely on CD8(+) T cells to fight against tumors. However accumulative evidence showed that proinflammatory CD4(+) helper T cells are critical determinants of effective antitumor immunity. The utilization of universal tumor-reactive helper peptides from telomerase represents a powerful approach to the fully use of CD4(+) T cell-based immunotherapy.

Keywords: CD4 T cell; cancer vaccine; helper peptide; telomerase.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Cancer Vaccines / administration & dosage
  • Cancer Vaccines / immunology*
  • Humans
  • Immunotherapy / methods*
  • Neoplasms / therapy*
  • T-Lymphocytes, Helper-Inducer / immunology*
  • Telomerase / immunology*
  • Vaccines, Subunit / administration & dosage
  • Vaccines, Subunit / immunology*

Substances

  • Cancer Vaccines
  • Vaccines, Subunit
  • Telomerase